About IgAN

Recognizing the heterogeneous presentation of IgAN is key to evaluating your patient’s disease¹

Factors to consider when evaluating patients with IgAN: Age and race, blood pressure, eGFR, current & prior therapies (ACEi, ARB, steroids), MEST-C score, Hematuria, Proteinuria levels.

Persistent proteinuria* could be a signal of disease progression in your patients with IgAN¹

*Persistent proteinuria ≥1.5 g/g is generally considered at risk for rapid disease progression in adults with primary IgAN.¹

OVER HALF of patients with IgAN continue to display persistent proteinuria at 3 months despite optimized doses of RASis, like an ACEi or ARB²

According to KDIGO guidelines, proteinuria <1 g/day is a reasonable treatment target in IgAN¹

How does IgAN impact your patients?

Meet Vince: A patient with IgAN and persistent proteinuria

There could be another option to lower proteinuria for patients like Vince³

Initial presentation to nephrologist¹

Proteinuria (g/g): 1.9
eGFR (mL/min/1.73 m²): 63
BP (mm Hg): 131/85
Comorbidities: None

Vince’s nephrologist suspects IgA nephropathy (IgAN) and sends him for a biopsy. The biopsy confirms an IgAN diagnosis so he is started on an ACEi and lifestyle changes (low-sodium diet and exercise). His nephrologist dose adjusts to the maximally tolerated and stable dose of his ACEi.

Hypothetical patient case and portrayal.

6-month follow-up shows proteinuria is still persistent^1,3,4

Proteinuria (g/g): 1.5
eGFR (mL/min/1.73 m²): 62
BP (mm Hg): 125/80

What would you consider doing next for this patient, and what treatment goals would you have?

Explore the pathogenesis of IgAN

Activation of the ET_A receptor by ET-1 is thought to contribute to the pathogenesis of IgAN⁵

In IgAN, there is an increase in galactose-deficient IgA1. This induces production of autoantibodies. Autoantibodies bind to Gd-IgA1 to form immune complexes. Immune complex deposition in the mesangium of the kidneys can activate multiple pathways. Multiple pathways, including increased ETA receptor signaling through increased ET-1 production, are triggered by immune complex deposition, which may result in damaging effects.

Kohan DE, Barratt J, Heerspink HJL, et al. Targeting the endothelin A receptor in IgA nephropathy. Kidney Int Rep. 2023;8(11):2198-2210. doi:10.1016/j.ekir.2023.07.023

How does VANRAFIA work?

See the mechanism of action

Ready to see what’s possible with VANRAFIA?

View the clinical results

About IgAN

Recognizing the heterogeneous presentation of IgAN is key to evaluating your patient’s disease¹

Persistent proteinuria* could be a signal of disease progression in your patients with IgAN¹

How does IgAN impact your patients?

Meet Vince: A patient with IgAN and persistent proteinuria

What would you consider doing next for this patient, and what treatment goals would you have?

Explore the pathogenesis of IgAN

Activation of the ET_A receptor by ET-1 is thought to contribute to the pathogenesis of IgAN⁵

How does VANRAFIA work?

Ready to see what’s possible with VANRAFIA?

Important Safety Information

Indication

Definitions and References

About IgAN

Recognizing the heterogeneous presentation of IgAN is key to evaluating your patient’s disease1

Persistent proteinuria* could be a signal of disease progression in your patients with IgAN¹

How does IgAN impact your patients?

Meet Vince: A patient with IgAN and persistent proteinuria

What would you consider doing next for this patient, and what treatment goals would you have?

Explore the pathogenesis of IgAN

Activation of the ETA receptor by ET-1 is thought to contribute to the pathogenesis of IgAN5

How does VANRAFIA work?

Ready to see what’s possible with VANRAFIA?

Definitions and References

Recognizing the heterogeneous presentation of IgAN is key to evaluating your patient’s disease¹

Activation of the ET_A receptor by ET-1 is thought to contribute to the pathogenesis of IgAN⁵